Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China

Figure 1 Viral elimination by all-oral direct acting antiviral treatment reduces rate of hepatocellular carcinoma in hepatitis C virus-infected patients. Japanese patients with GT1 hepatitis C virus infection initiating all-oral direct acting antiviral treatment between September 2014 and May 2016 were followed up for a range of 0.1–2.2 years (median follow-up period 1.3 years). The number of patients at risk is shown below each time point. Patients who achieved sustained virologic response had significantly lower incidence of hepatocellular carcinoma compared to patients without sustained virologic response. ^aP = 0.007, log-rank test. SVR: Sustained virologic response. Adapted with permission from Ogata et al[27], 2017.